Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium Patent Expiration

Elagolix Sodium,Estradiol,Norethindrone Acetate; Elagolix Sodium is Used for managing heavy menstrual bleeding associated with uterine leiomyomas (fibroids) with the use of elagolix and omeprazole. It was first introduced by Abbvie Inc in its drug Oriahnn (Copackaged) on May 29, 2020.


Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium Patents

Given below is the list of patents protecting Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Oriahnn (copackaged) US11690845 Methods of administering elagolix Aug 27, 2040 Abbvie
Oriahnn (copackaged) US11542239 Elagolix sodium compositions and processes Jul 23, 2039 Abbvie
Oriahnn (copackaged) US12083227 Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis Aug 20, 2038 Abbvie
Oriahnn (copackaged) US10881659 Methods of treating heavy menstrual bleeding Mar 14, 2034 Abbvie
Oriahnn (copackaged) US11045470 Methods of treating heavy menstrual bleeding Mar 14, 2034 Abbvie
Oriahnn (copackaged) US7419983 Gonadotropin-releasing hormone receptor antagonists and methods related thereto Jul 06, 2029 Abbvie
Oriahnn (copackaged) US11459305 Processes for the preparation of uracil derivatives Nov 07, 2028 Abbvie
Oriahnn (copackaged) US7056927 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Sep 10, 2024

(Expired)

Abbvie
Oriahnn (copackaged) US7179815 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Mar 07, 2021

(Expired)

Abbvie
Oriahnn (copackaged) US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jan 25, 2021

(Expired)

Abbvie
Oriahnn (copackaged) US7462625 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jan 25, 2021

(Expired)

Abbvie



Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List